Venous Thromboembolism (VTE): Risk, Prevention and Management

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pulmonary Medicine, Hospital Clínic–Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERES, University of Barcelona, 08036 Barcelona, Spain
Interests: pulmonary embolism; right ventricle failure; biomarkers; risk stratification; non-coding RNAs; critical care

Special Issue Information

Dear Colleagues,

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a major global health concern. It is a leading cause of morbidity and mortality, particularly in hospitalized patients, individuals with cancer, and those with genetic predispositions. Despite significant advances, VTE diagnosis and management continue to pose challenges, requiring ongoing research and innovation.

Current strategies for VTE prevention include pharmacological approaches, such as anticoagulation therapy, and mechanical methods, such as compression devices. However, balancing the effectiveness of anticoagulants with the risk of bleeding complications remains a key concern. New anticoagulant therapies and risk stratification models are being developed to improve patient outcomes. Advances in biomarkers and imaging techniques are also enhancing early detection and treatment precision.

Recent years have seen the emergence of novel reperfusion and supportive strategies for severe cases, including catheter-directed techniques and surgical interventions. Multidisciplinary approaches are becoming increasingly important in optimizing patient care. Additionally, high-risk populations, such as gender-specific groups, cancer patients, and individuals with prolonged immobility, require tailored prevention and treatment strategies. Integrating artificial intelligence (AI) into VTE diagnosis and management is also being explored to enhance predictive modeling and clinical decision-making.

By bringing together expert perspectives, this Special Issue will enhance understanding and optimize VTE management. It serves as a valuable resource for clinicians, researchers, and healthcare professionals striving to reduce VTE-related complications and improve patient outcomes through evidence-based strategies and innovative approaches.

This Special Issue will compile and contextualize recent progress in the field of venous thromboembolism. It will highlight new findings in the pathophysiology, diagnosis, and treatment of VTE, bringing together original research, comprehensive reviews, and case studies to provide a robust reference for ongoing clinical and research endeavors.

Dr. Jorge Moisés
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary embolism
  • cardiogenic shock
  • right ventricle failure
  • biomarkers
  • risk stratification
  • PE treatment
  • reperfusion
  • artificial intelligence
  • bleeding

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 406 KB  
Article
Clinical Outcomes and Treatment Strategies in Catastrophic High-Risk Pulmonary Embolism: A Retrospective Analysis
by María Caridad Mata, Ignacio Español, Arantxa Gelabert, Jesús Aibar, Núria Albacar, Elena Sandoval, Pedro Castro, Sònia Jiménez, Jeisson Osorio and Jorge Moisés
J. Cardiovasc. Dev. Dis. 2025, 12(12), 459; https://doi.org/10.3390/jcdd12120459 - 25 Nov 2025
Abstract
High-risk pulmonary embolism (PE) is a life-threatening condition characterized by hemodynamic instability, often leading to catastrophic outcomes such as cardiac arrest and cardiogenic shock. We conducted a retrospective analysis of patients diagnosed with high-risk PE at a single tertiary center between 2018 and [...] Read more.
High-risk pulmonary embolism (PE) is a life-threatening condition characterized by hemodynamic instability, often leading to catastrophic outcomes such as cardiac arrest and cardiogenic shock. We conducted a retrospective analysis of patients diagnosed with high-risk PE at a single tertiary center between 2018 and 2024. Catastrophic PE was defined as high-risk PE with hemodynamic collapse, including cardiac arrest and/or the requirement for high-dose vasopressors. Data on clinical characteristics, treatments, and outcomes were analyzed. Catastrophic PE accounted for 59% of cases. Systemic thrombolysis was the most frequent reperfusion strategy (67%), while catheter-directed therapies (35.4%) and VA-ECMO (11.4%) were used selectively. Despite aggressive management, catastrophic PE exhibited significantly higher mortality rates at 7 days (40%) and 30 days (49%) compared to non-catastrophic cases (9% and 12.5%, respectively). These patients also showed higher rates of multiorgan failure and required more invasive support. This study underscores the importance of early recognition and tailored treatment strategies for catastrophic PE, highlighting its distinct clinical presentation and worse outcomes compared to non-catastrophic high-risk PE. Further research is essential to refine treatment protocols and improve survival in this critically ill population, emphasizing the utility of a standardized classification to enhance clinical management and research consistency. Full article
(This article belongs to the Special Issue Venous Thromboembolism (VTE): Risk, Prevention and Management)
Show Figures

Graphical abstract

Back to TopTop